Floatz logo

Irinotecan

Ovarian Mucinous Cystadenocarcinoma

National Cancer Institute (NCI)Small moleculePhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Ovarian Mucinous Cystadenocarcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
Gynecologic Oncology Group
Phase 3BB
Capecitabine
National Cancer Institute (NCI)
Phase 3BB
Eloxatin
National Cancer Institute (NCI)
Phase 3BB
(+)-VINCRISTINE
National Cancer Institute (NCI)
Phase 3BB
FILGRASTIM
University of Washington
Phase 2B

View all 29 →

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →